


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims

1. - 20. (Cancelled)


21. (Currently amended) A compound of formula I:



in free or salt or ~~solvate~~ form, where

R¹ is hydroxy and R² is hydrogen;

G is a group having the formula Ib:



C~C denotes C=C or CH-CH;

R⁷ and R⁸ are both hydrogen;

R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen and C₁-C₁₀ alkyl, or R⁹ and R¹⁰ together form a C₃-C₁₀ cycloalkyl or C₃-C₁₀ cycloalkenyl, and in either case wherein R⁹ and R¹⁰ are optionally substituted by C₁-C₁₀ alkyl; and

R¹¹ is a C₃-C₁₅ carbocyclic group or C₁-C₁₀ alkyl substituted by a C₃-C₁₅ carbocyclic group.

22. (Previously presented) The compound according to claim 21, wherein:

R¹ is hydroxy and R² is hydrogen;

C~C denotes C=C or CH-CH;

R⁷ and R⁸ are both hydrogen;

R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen or C₁-C₄ alkyl, or R⁹ and R¹⁰ together form a C₃-C₆ cycloalkyl or C₃-C₆ cycloalkenyl, and in either case wherein R⁹

and R¹⁰ are optionally substituted by C₁-C₄ alkyl; and
R¹¹ is a C₃-C₁₀ carbocyclic or C₁-C₁₀ alkyl substituted by a C₃-C₁₀ carbocyclic group.

23. (Previously presented) The compound according to claim 22, wherein R¹¹ is a C₃-C₆ cycloalkyl.

24. (Previously presented) The compound according to claim 22, wherein R¹¹ is a C₁-C₁₀ alkyl substituted by an unsaturated C₅-C₈ carbocyclic group.

25. (Previously presented) The compound according to claim 21 that is:

5-[R-2-(1S,2S-2-Cyclohexylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one;

5-[R-2-(1R,2R-2-cyclohexylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one;

5-[R-2-(1R,2R-bicyclopentyl-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; or

5-[R-2-(1R,2R-2-Benzylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one.

26. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 21.

27. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 21 and at least one pharmaceutically acceptable carrier.


28. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 21 and a therapeutically effective amount of another drug substance selected from the group consisting of an anti-inflammatory, a bronchodilator, an antihistamine, an immunosuppressive and an anti-tussive.

29. (Cancelled).

30. (Previously presented) A method of treating a patient with obstructive or inflammatory airways disease by administering a therapeutically effective amount of at least one compound according to claim 21.

31. (Currently amended) A process for the preparation of a compound of claim 21 in free or salt or solvate form comprising:


(A) reacting a compound of formula II:



or a protected form thereof wherein R¹ and R² are as defined in claim 21, with a compound of formula III:



where G is a group of formula Ib:




or a protected form thereof wherein R⁷, R⁸, R⁹, R¹⁰ and R¹¹ are as defined in claim 21;
and

(B) recovering the resultant compound of formula I in free or salt ~~or solvate~~ form.

32. (Currently amended) A process for the preparation of a compound of claim 21 in free or salt ~~or solvate~~ form comprising:

(A) reducing a compound of formula IV:



or a protected form thereof wherein R¹, R² and G are as defined in claim 21, to convert the indicated keto group into -CH(OH); and

(B) recovering the resultant compound of formula I in free or salt ~~or solvate~~ form.

33. (New) The method of claim 30 wherein the obstructive or inflammatory airways disease is asthma, adult/acute respiratory distress syndrome, chronic obstructive pulmonary or airways disease, chronic bronchitis or dyspnea associated therewith, emphysema, exacerbation of airways hyperreactivity consequent to other drug therapy, bronchitis or pneumoconiosis.